Biotech | April 05, 2022
Lupin signs deal with Alvion for cardiometabolic drugs in Southeast Asia
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Subscribe To Our Newsletter & Stay Updated
